TrialBlood advances2025

Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial.

Carsten U Niemann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.